These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 14761197)

  • 1. Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels.
    Marivingt-Mounir C; Norez C; Dérand R; Bulteau-Pignoux L; Nguyen-Huy D; Viossat B; Morgant G; Becq F; Vierfond JM; Mettey Y
    J Med Chem; 2004 Feb; 47(4):962-72. PubMed ID: 14761197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein.
    Melin P; Thoreau V; Norez C; Bilan F; Kitzis A; Becq F
    Biochem Pharmacol; 2004 Jun; 67(12):2187-96. PubMed ID: 15163550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
    Norez C; Bilan F; Kitzis A; Mettey Y; Becq F
    J Pharmacol Exp Ther; 2008 Apr; 325(1):89-99. PubMed ID: 18230692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel.
    Becq F; Mettey Y; Gray MA; Galietta LJ; Dormer RL; Merten M; Métayé T; Chappe V; Marvingt-Mounir C; Zegarra-Moran O; Tarran R; Bulteau L; Dérand R; Pereira MM; McPherson MA; Rogier C; Joffre M; Argent BE; Sarrouilhe D; Kammouni W; Figarella C; Verrier B; Gola M; Vierfond JM
    J Biol Chem; 1999 Sep; 274(39):27415-25. PubMed ID: 10488073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of alpha-aminoazaheterocycle-methylglyoxal adducts as a new class of high-affinity inhibitors of cystic fibrosis transmembrane conductance regulator chloride channels.
    Routaboul C; Norez C; Melin P; Molina MC; Boucherle B; Bossard F; Noel S; Robert R; Gauthier C; Becq F; Décout JL
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1023-35. PubMed ID: 17578899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of pyrrolo[2,3-b]pyrazines derivatives as submicromolar affinity activators of wild type, G551D, and F508del cystic fibrosis transmembrane conductance regulator chloride channels.
    Noel S; Faveau C; Norez C; Rogier C; Mettey Y; Becq F
    J Pharmacol Exp Ther; 2006 Oct; 319(1):349-59. PubMed ID: 16829626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease.
    Pasyk S; Li C; Ramjeesingh M; Bear CE
    Biochem J; 2009 Feb; 418(1):185-90. PubMed ID: 18945216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells.
    Dormer RL; Dérand R; McNeilly CM; Mettey Y; Bulteau-Pignoux L; Métayé T; Vierfond JM; Gray MA; Galietta LJ; Morris MR; Pereira MM; Doull IJ; Becq F; McPherson MA
    J Cell Sci; 2001 Nov; 114(Pt 22):4073-81. PubMed ID: 11739639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation.
    Dérand R; Bulteau-Pignoux L; Mettey Y; Zegarra-Moran O; Howell LD; Randak C; Galietta LJ; Cohn JA; Norez C; Romio L; Vierfond JM; Joffre M; Becq F
    Am J Physiol Cell Physiol; 2001 Nov; 281(5):C1657-66. PubMed ID: 11600430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel.
    Chappe V; Mettey Y; Vierfond JM; Hanrahan JW; Gola M; Verrier B; Becq F
    Br J Pharmacol; 1998 Feb; 123(4):683-93. PubMed ID: 9517388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners.
    Li C; Naren AP
    Pharmacol Ther; 2005 Nov; 108(2):208-23. PubMed ID: 15936089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of natural coumarin compounds that rescue defective DeltaF508-CFTR chloride channel gating.
    Xu LN; Na WL; Liu X; Hou SG; Lin S; Yang H; Ma TH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):878-83. PubMed ID: 18430055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of salivary secretion in vivo by CFTR potentiators in Cftr+/+ and Cftr-/- mice.
    Noël S; Strale PO; Dannhoffer L; Wilke M; DeJonge H; Rogier C; Mettey Y; Becq F
    J Cyst Fibros; 2008 Mar; 7(2):128-33. PubMed ID: 17766192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rescue of DeltaF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network.
    Lipecka J; Norez C; Bensalem N; Baudouin-Legros M; Planelles G; Becq F; Edelman A; Davezac N
    J Pharmacol Exp Ther; 2006 May; 317(2):500-5. PubMed ID: 16424149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- currents by the chemical solvent tetrahydrofuran.
    Hughes LK; Ju M; Sheppard DN
    Mol Membr Biol; 2008 Sep; 25(6-7):528-38. PubMed ID: 18989824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ATP-sensitive K+ channels by substituted benzo[c]quinolizinium CFTR activators.
    Prost A; Dérand R; Gros L; Becq F; Vivaudou M
    Biochem Pharmacol; 2003 Aug; 66(3):425-30. PubMed ID: 12907241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07.
    Zegarra-Moran O; Romio L; Folli C; Caci E; Becq F; Vierfond JM; Mettey Y; Cabrini G; Fanen P; Galietta LJ
    Br J Pharmacol; 2002 Oct; 137(4):504-12. PubMed ID: 12359632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-aminoazaheterocyclic-methylglyoxal adducts do not inhibit cystic fibrosis transmembrane conductance regulator chloride channel activity.
    Sonawane ND; Zegarra-Moran O; Namkung W; Galietta LJ; Verkman AS
    J Pharmacol Exp Ther; 2008 May; 325(2):529-35. PubMed ID: 18272811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genistein modifies the activation kinetics and magnitude of phosphorylated wild-type and G551D-CFTR chloride currents.
    Bulteau-Pignoux L; Dérand R; Métayé T; Joffre M; Becq F
    J Membr Biol; 2002 Aug; 188(3):175-82. PubMed ID: 12181609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule modulator interacts directly with deltaPhe508-CFTR to modify its ATPase activity and conformational stability.
    Wellhauser L; Kim Chiaw P; Pasyk S; Li C; Ramjeesingh M; Bear CE
    Mol Pharmacol; 2009 Jun; 75(6):1430-8. PubMed ID: 19339490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.